| # | Drug | Count |
|---|---|---|
| 0 | PANITUMUMAB | 1069 |
| 1 | CETUXIMAB | 856 |
| 2 | FLUOROURACIL | 705 |
| 3 | FLUOROURACIL CREAM, 0.5% | 704 |
| 4 | OXALIPLATIN | 615 |
| 5 | BEVACIZUMAB | 299 |
| 6 | ERLOTINIB HYDROCHLORIDE | 232 |
| 7 | CARBOPLATIN | 223 |
| 8 | ADALIMUMAB | 207 |
| 9 | ACETAMINOPHEN | 189 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CLINDAMYCIN PHOSPHATE TOPICAL SOLUTION USP, 1% | 2 | 0.1538 |
| 1 | PANITUMUMAB | 1069 | 0.0664 |
| 2 | SELUMETINIB | 84 | 0.0499 |
| 3 | LAZERTINIB | 31 | 0.0358 |
| 4 | TOVORAFENIB | 10 | 0.0307 |
| 5 | CETUXIMAB | 856 | 0.0270 |
| 6 | AFATINIB | 152 | 0.0230 |
| 7 | LEVOLEUCOVORIN INJECTION | 68 | 0.0221 |
| 8 | AMIVANTAMAB-VMJW | 76 | 0.0213 |
| 9 | AVUTOMETINIB POTASSIUM AND DEFACTINIB HYDROCHLORIDE | 21 | 0.0187 |
| # | Drug class | Count |
|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1890 |
| 1 | Platinum-based Drug [EPC] | 964 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 865 |
| 3 | Kinase Inhibitor [EPC] | 673 |
| 4 | Corticosteroid [EPC] | 471 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 370 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 305 |
| 7 | Microtubule Inhibitor [EPC] | 261 |
| 8 | Benzodiazepine [EPC] | 220 |
| 9 | Proton Pump Inhibitor [EPC] | 217 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1890 | 0.0400 |
| 1 | Gamma Secretase Inhibitor [EPC] | 11 | 0.0119 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 33 | 0.0052 |
| 3 | Tyrosine Kinase 2 Inhibitor [EPC] | 13 | 0.0044 |
| 4 | Lymphocyte Activation Gene-3 Blocker [EPC] | 2 | 0.0039 |
| 5 | Platinum-based Drug [EPC] | 964 | 0.0035 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 865 | 0.0032 |
| 7 | Pyrethroid [EPC] | 5 | 0.0028 |
| 8 | Vitamin B6 Analog [EPC] | 1 | 0.0028 |
| 9 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 1 | 0.0026 |